Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
Irish Independent on MSN
Innovative therapy gives hope to patients whose blood cancer ‘seemed incurable’
Almost two thirds of patients with T-cell acute lymphoblastic leukaemia involved in a clinical trial of the treatment are now ...
A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell leukemia.
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street ...
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback